Promising kidney drug study for babies pulled before it began
NCT ID NCT04786574
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 29 times
Summary
This study planned to test the drug tolvaptan in very young infants (28 days to under 12 weeks old) with a rare, severe kidney disease called ARPKD. The goal was to see if the drug could reduce the need for dialysis or a kidney transplant in the first year of life. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.